Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer H Foster

Showing results (41-50 of 51) with videos related to

Pageof 6
Sort By:
Pediatric Blood & Cancer|March 13, 2026
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective StudyBenjamin J Lerman, Madeleine King, Rajen Mody, et al.
Cancer|June 6, 2022
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual diseaseAmi V Desai, Mark A Applebaum, Theodore G Karrison, et al.
Nature Communications|June 28, 2022
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastomaLing Tao, Mahmoud A Mohammad, Giorgio Milazzo, et al.
Cancer Letters|May 18, 2019
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signalingHui Li, Yang Yu, Yanling Zhao, et al.
Pediatric Blood & Cancer|March 24, 2025
Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical TrialDavid R Freyer, Timothy J D Ohlsen, Debra Don, et al.
Cancer|February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastomaSteven G DuBois, Chitose Ogawa, Lucas Moreno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin J Lerman, Yimei Li, Cecilia Carlowicz, et al.
Neuro-Oncology|April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)Ami V Desai, Giles W Robinson, Karen Gauvain, et al.
JAMA Oncology|August 12, 2021
Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus ReportAnnelot J M Meijer, Marry M van den Heuvel-Eibrink, Beth Brooks, et al.
Pediatrics|December 1, 2021
Preventing Home Medication Administration ErrorsH Shonna Yin, Daniel R Neuspiel, Ian M Paul, et al.
Pageof 6

Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Pediatric Blood & Cancer|March 13, 2026
Efficacy and Tolerability of Topotecan/Cyclophosphamide/Dinutuximab in Relapsed and Refractory High-Risk Neuroblastoma: A Multi-Institutional Retrospective StudyBenjamin J Lerman, Madeleine King, Rajen Mody, et al.
Cancer|June 6, 2022
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual diseaseAmi V Desai, Mark A Applebaum, Theodore G Karrison, et al.
Nature Communications|June 28, 2022
MYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastomaLing Tao, Mahmoud A Mohammad, Giorgio Milazzo, et al.
Cancer Letters|May 18, 2019
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signalingHui Li, Yang Yu, Yanling Zhao, et al.
Pediatric Blood & Cancer|March 24, 2025
Feasibility and Safety of Intratympanic Administration of Sustained-Exposure Dexamethasone Thermosensitive Gel (OTO-104) for Prevention of Cisplatin-Induced Hearing Loss in Children: A Multisite Phase 2 Randomized Clinical TrialDavid R Freyer, Timothy J D Ohlsen, Debra Don, et al.
Cancer|February 11, 2025
A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastomaSteven G DuBois, Chitose Ogawa, Lucas Moreno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 7, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin J Lerman, Yimei Li, Cecilia Carlowicz, et al.
Neuro-Oncology|April 8, 2022
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)Ami V Desai, Giles W Robinson, Karen Gauvain, et al.
JAMA Oncology|August 12, 2021
Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment: An International Society of Paediatric Oncology Supportive Care Consensus ReportAnnelot J M Meijer, Marry M van den Heuvel-Eibrink, Beth Brooks, et al.
Pediatrics|December 1, 2021
Preventing Home Medication Administration ErrorsH Shonna Yin, Daniel R Neuspiel, Ian M Paul, et al.
Pageof 6